Eisaku Iwanaga, Tomoko Nanri, Naofumi Matsuno, Toshiro Kawakita, Hiroaki Mitsuya, Norio Asou. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia. Haematologica 2009;94(3):433-435; https://doi.org/10.3324/haematol.13283.